https://www.selleckchem.com/products/lc-2.html 96, 95% confidence interval [CI]=1.3-6.9; p= 0.012), and tumor histologic type (clear cell/endometrioid vs. mucinous; OR32.8, 95% CI=6.9-154.8, p< 0.001; clear cell/endometrioid vs. serous OR 48.1, 95% CI=8.8-261.8, p< 0.001) were independent risk factors for an upgrade of the permanent diagnosis from a BOT to ovarian carcinoma. An elevated CA-125 level (over 136 U/mL) and tumor histologic type (clear cell and endometrioid subtypes) were associated with an upgrade in the diagnosis of ovarian tumor from a BOT on frozen section to a permanent diagnosis of malignancy. An elevated CA-125 level (over 136 U/mL) and tumor histologic type (clear cell and endometrioid subtypes) were associated with an upgrade in the diagnosis of ovarian tumor from a BOT on frozen section to a permanent diagnosis of malignancy. Neratinib has efficacy in central nervous system (CNS) metastases from HER2-positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus capecitabine (N+C) versus lapatinib plus capecitabine (L+C). NALA was a randomized, active-controlled trial in patients who received two or more previous HER2-directed regimens for HER2-positive MBC. Patients with asymptomatic/stable brain metastases (treated or untreated) were eligible. Patients were assigned to N+C (neratinib 240 mg per day, capecitabine 750 mg/m twice daily) or L+C (lapatinib 1,250 mg per day, capecitabine 1,000 mg/m twice daily) orally. Independently adjudicated progression-free survival (PFS), overall survival (OS), and CNS endpoints were considered. Of 621 patients enrolled, 101 (16.3%) had known CNS metastases at baseline (N+C, n= 51; L+C, n= 50); 81 had received prior CNS-directed radiotherapy and/or surgery. In the CNS subgroup, mean PFS through 2plus capecitabine. These findings build on previous phase II and III studies describing efficacy of neratinib in the preventio